Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan 31;14(1):1-3.
doi: 10.21037/tau-24-529. Epub 2025 Jan 16.

Balancing risks and benefits in the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer

Samantha Unsworth-White  1 , Nada Humayun-Zakaria  2   3 , Richard T Bryan  3
Affiliations
Editorial

Balancing risks and benefits in the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer

Samantha Unsworth-White et al. Transl Androl Urol. .
No abstract available

Keywords: Atezolizumab; Bacillus Calmette-Guerin-unresponsive (BCG-unresponsive); circulating-tumour DNA (ctDNA); immuno-oncology; non-muscle-invasive bladder cancer (NMIBC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-24-529/coif). R.T.B. has received research funding from the UK NIHR HTA programme, Cancer Research UK, Janssen, University Hospitals Birmingham Charity (UK), QED Therapeutics (USA), and UroGen Pharma (USA). He is an unpaid charity trustee for Action Bladder Cancer UK (UK), an advisory board member for Nonacus Limited (UK), and receives consultancy fees from Cystotech ApS (Denmark) and Informed Genomics Limited (UK). The other authors have no conflicts of interest to declare.

Comment on

References

    1. Catto JWF, Gordon K, Collinson M, et al. Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study. J Clin Oncol 2021;39:202-14. 10.1200/JCO.20.01665 - DOI - PMC - PubMed
    1. Catto JWF, Khetrapal P, Ricciardi F, et al. Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial. JAMA 2022;327:2092-103. 10.1001/jama.2022.7393 - DOI - PMC - PubMed
    1. Ward K, Kitchen MO, Mathias SJ, et al. Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning. Front Surg 2022;9:912438. 10.3389/fsurg.2022.912438 - DOI - PMC - PubMed
    1. Black PC, Tangen CM, Singh P, et al. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol 2023;84:536-44. 10.1016/j.eururo.2023.08.004 - DOI - PMC - PubMed
    1. Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 2021;595:432-7. 10.1038/s41586-021-03642-9 - DOI - PubMed